Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372588 | 0.98 | KDM4E (0.54) | KDM4ECHRM2CHRM4CHRM5CYP2D6 | |
| SCHEMBL4902574 | 0.87 | KDM4E (0.56) | KDM4E | |
| SCHEMBL4901669 | 0.85 | KDM4E (0.60) | KDM4ECHRM2CHRM4CHRM5CYP2D6 | |
| SCHEMBL898004 | 0.84 | KDM4E (0.48) | KDM4E | |
| SCHEMBL17586120 | 0.83 | CHRM2 (0.40) | KDM4ECHRM2CHRM4CHRM5CYP2D6 | |
| SCHEMBL22121558 | 0.82 | KDM4E (0.50) | KDM4E | |
| SCHEMBL3307850 | 0.82 | KDM4E (0.52) | KDM4ECHRM2CHRM4CHRM5CYP2D6 | |
| SCHEMBL17586126 | 0.81 | CHRM2 (0.39) | KDM4ECHRM2CHRM4CHRM5CYP2D6 | |
| SCHEMBL21315188 | 0.81 | KDM4E (0.50) | KDM4E | |
| SCHEMBL17581645 | 0.81 | CHRM2 (0.39) | KDM4ECHRM2CHRM4CHRM5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921589-B2 | Electrolyte formulations | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | claimed |
| US-8829201-B2 | Electrolyte Formulations | MERCK PATENT GMBH (DE) | 2014-09-09 | — | — | US | claimed |
| US-20120318360-A1 | Electrolyte Formulations | MERCK PATENT GMBH (DE) | 2012-12-20 | — | — | US | claimed |
| US-12612548-B2 | Method for producing inorganic fluoride luminescent material | NICHIA CORPORATION (JP) | 2026-04-28 | — | — | US | disclosed |
| US-20230220275-A1 | METHOD FOR PRODUCING INORGANIC FLUORIDE LUMINESCENT MATERIAL | NICHIA CORPORATION (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230159842-A1 | IONIC LIQUID INCLUDING FLUORINE-CONTAINING PHOSPHATE ESTER ANIONS, AND LUBRICATING OIL COMPOSITION | NISSHINBO HOLDINGS INC. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230142294-A1 | PRODUCTION METHOD OF INORGANIC FLUORIDE LUMINESCENT MATERIAL | NICHIA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4134413-A1 | IONIC LIQUID INCLUDING FLUORINE-CONTAINING PHOSPHATE ESTER ANIONS, AND LUBRICATING OIL COMPOSITION | Nisshinbo Holdings Inc. (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-11114695-B2 | Electrolyte for electrochemical device, electrolytic solution, and electrochemical device | OTSUKA CHEMICAL CO., LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| US-RE48165-E1 | Alkenyl (perfluoroalkyl) phosphinic acids | MERCK PATENT GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| US-20190273284-A1 | ELECTROLYTE FOR ELECTROCHEMICAL DEVICE, ELECTROLYTIC SOLUTION, AND ELECTROCHEMICAL DEVICE | OTSUKA CHEMICAL CO., LTD. (JP) | 2019-09-05 | — | — | US | disclosed |
| WO-2011085964-A1 | ELECTROLYTE FORMULATIONS | MERCK PATENT GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011085965-A1 | ELECTROLYTE FORMULATIONS | MERCK PATENT GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011085967-A1 | COMPOUNDS CONTAINING PERFLUOROALKYL-CYANO-ALKOXY-BORATE ANIONS OR PERFLUOROALKYL-CYANO-ALKOXY-FLUORO-BORATE ANIONS | MERCK PATENT GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011072810-A1 | COMPOUNDS WITH (PERFLUORALKYL)FLUORO-HYDROGENPHOSPHATE ANIONS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-20100099031-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2166611-A1 | NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20080271381-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | POLYPLASTICS CO., LTD (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1867667-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | Polyplastics Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20060186419-A1 | Light-emitting device | KABUSHIKI KAISHA TOSHIBA (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120318360-A1 | Electrolyte Formulations | NHERF1, HCN4, DDT | KDM4E 1254/4885CHRM2 2507/4885CHRM4 1642/4885 |
| US-20230159842-A1 | IONIC LIQUID INCLUDING FLUORINE-CONTAINING PHOSPHATE ESTER ANIONS, AND LUBRICATING OIL COMPOSITION | PHOSPHO1, FGFR1, PLCB3 | KDM4E 4484/4885CHRM2 2328/4885CHRM4 1789/4885 |
| US-12612548-B2 | Method for producing inorganic fluoride luminescent material | FLNA, F7, NPM1 | KDM4E 2254/4885CHRM2 1283/4885CHRM4 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.